342 related articles for article (PubMed ID: 24176494)
1. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.
Leroux-Roels I; Devaster JM; Leroux-Roels G; Verlant V; Henckaerts I; Moris P; Hermand P; Van Belle P; Poolman JT; Vandepapelière P; Horsmans Y
Vaccine; 2015 Jan; 33(4):577-84. PubMed ID: 24176494
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
Pauksens K; Nilsson AC; Caubet M; Pascal TG; Van Belle P; Poolman JT; Vandepapelière PG; Verlant V; Vink PE
Clin Vaccine Immunol; 2014 May; 21(5):651-60. PubMed ID: 24599529
[TBL] [Abstract][Full Text] [Related]
3. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.
Brooks WA; Chang LJ; Sheng X; Hopfer R;
Vaccine; 2015 Aug; 33(36):4610-7. PubMed ID: 26143615
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults.
Seiberling M; Bologa M; Brookes R; Ochs M; Go K; Neveu D; Kamtchoua T; Lashley P; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7455-60. PubMed ID: 23131206
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
[TBL] [Abstract][Full Text] [Related]
8. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
Prymula R; Pazdiora P; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 May; 32(25):3025-34. PubMed ID: 24699466
[TBL] [Abstract][Full Text] [Related]
10. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants.
Malekan M; Siadat SD; Aghasadeghi M; Shahrokhi N; Afrough P; Behrouzi A; Ahmadi K; Mousavi SF
J Med Microbiol; 2020 Mar; 69(3):465-477. PubMed ID: 32100705
[No Abstract] [Full Text] [Related]
12. Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.
Berglund J; Vink P; Tavares Da Silva F; Lestrate P; Boutriau D
Clin Vaccine Immunol; 2014 Jan; 21(1):56-65. PubMed ID: 24173029
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.
Kamtchoua T; Bologa M; Hopfer R; Neveu D; Hu B; Sheng X; Corde N; Pouzet C; Zimmermann G; Gurunathan S
Vaccine; 2013 Jan; 31(2):327-33. PubMed ID: 23153437
[TBL] [Abstract][Full Text] [Related]
14. Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.
Brookes RH; Ming M; Williams K; Hopfer R; Gurunathan S; Gallichan S; Tang M; Ochs MM
Hum Vaccin Immunother; 2015; 11(7):1836-9. PubMed ID: 25912273
[TBL] [Abstract][Full Text] [Related]
15. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
Denoël P; Philipp MT; Doyle L; Martin D; Carletti G; Poolman JT
Vaccine; 2011 Jul; 29(33):5495-501. PubMed ID: 21624422
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Foster-Nyarko E; Owiafe PK; Ceesay F; Worwui A; Idoko OT; Owolabi O; Bojang A; Jarju S; Drammeh I; Kampmann B; Greenwood BM; Alderson M; Traskine M; Devos N; Schoonbroodt S; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2017 May; 35(19):2531-2542. PubMed ID: 28389097
[TBL] [Abstract][Full Text] [Related]
17. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.
Odutola A; Ota MO; Ogundare EO; Antonio M; Owiafe P; Worwui A; Greenwood B; Alderson M; Traskine M; Verlant V; Dobbelaere K; Borys D
Hum Vaccin Immunother; 2016; 12(2):393-402. PubMed ID: 26618243
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.
Odusanya OO; Kuyinu YA; Kehinde OA; Francois N; Yarzabal JP; Moreira M; Borys D; Schuerman L
Niger Postgrad Med J; 2013 Dec; 20(4):272-81. PubMed ID: 24633268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
